ERBB2 and cancer: Cancer‐related gene mutations were detected in most patients (81.63%, 120/147) including EGFR, MET, ERBB2, TP53, PIK3CA, PTEN, RB1, SMAD4, CTNNB1, CDKN2A, and MTOR, whereas 27 patients (18.36%) were negative in the NGS test (Fig 2a).